
Beth Marsh appointed as new Neurotech chief commercial officer
Beth Marsh is stepping into the role of Neurotech Pharmaceuticals’ chief commercial officer (CCO) beginning April 28. Marsh will lead the organization, particularly as it prepares for the US launch of revakinagene taroretcel-lwey (ENCELTO), approved for …